Skip to main content
Wockhardt Ltd logo

Wockhardt Ltd — Investor Relations & Filings

Ticker · WOCKPHARMA ISIN · INE049B01025 LEI · 3358001OC2OX7OZAHZ33 BSE.NS Manufacturing
Open in API
Filings indexed 861 across all filing types
Latest filing 2024-08-09 Capital/Financing Update
Country IN India
Listing BSE.NS WOCKPHARMA

About Wockhardt Ltd

https://www.wockhardt.com/

Wockhardt Ltd is a research-driven global organization focused on the development and manufacturing of formulations, biopharmaceuticals, and active pharmaceutical ingredients (APIs). The company maintains a specialized focus on drug discovery, particularly in the field of anti-infectives and New Chemical Entities (NCEs) aimed at addressing antimicrobial resistance. Its therapeutic portfolio encompasses diverse areas such as diabetes, nephrology, cardiology, and respiratory health. With a strong emphasis on research and development, the company operates multiple manufacturing facilities that comply with international regulatory standards. Wockhardt provides medical solutions across various international markets, utilizing its expertise in complex chemistry and biotechnology to address unmet clinical needs.

Recent filings

Filing Released Lang Actions
Monitoring Agency Report
Capital/Financing Update Classification · 95% confidence The document is titled 'Monitoring Agency Report for the quarter ended 30th June, 2024' and is issued pursuant to SEBI regulations related to the utilization of proceeds from a Qualified Institutional Placement (QIP). It includes detailed information on the use of funds raised through the QIP, certifications by independent chartered accountants, and comments from the monitoring agency and the board of directors. The report is comprehensive, covering financial details and compliance with regulatory requirements for the quarter ended June 30, 2024. This type of document is a regulatory compliance report related to capital raising and fund utilization, which fits best under the category of Capital/Financing Update (CAP). It is not an earnings release, annual report, or audit report, but a specific monitoring report on capital utilization as required by SEBI for QIP proceeds.
2024-08-09 English
Change in Auditors
Regulatory Filings
2024-08-09 English
Outcome of Board Meeting
Regulatory Filings
2024-08-09 English
Financial Result Updates
Regulatory Filings
2024-08-09 English
Change in Management
Board/Management Information Classification · 95% confidence The document is a formal notification addressed to the National Stock Exchange of India regarding the appointment of Amb. Ahmad Javed as an Additional (Independent) Director of Wockhardt Limited. It references compliance with Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, which pertains to disclosure of material events including changes in the board of directors. The content includes details about the appointment date, term, and brief profile of the appointee. There is no financial data, earnings information, or report publication mentioned. The document is clearly an announcement of a change in the company's board of directors, fitting the category of Board/Management Information (MANG). The document length is 4099 characters, which is sufficient for a detailed announcement but not a full report. Therefore, the appropriate classification is MANG with high confidence.
2024-08-05 English
Board Meeting — WOCKHARDT LIMITED has informed the Exchange about Board Meeting to be held on 09-Aug-2024 to inter-alia consider and approve the Unaudited Financial results of the Company for the Qua…
Regulatory Filings
2024-08-05 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.